Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates

Maha Farhat, Jaimie Sixsmith, Róger Calderón, Nathan Hicks, Sarah M. Fortune, Megan MurrayJournal of Antimicrobial Chemotherapy 2019 · DOI

Abstract

The observation that the rpoB D435V mutation produces an increase in the IC50 of both drugs contrasts with findings from previous smaller studies that suggested that isolates with the D435V mutation remain rifabutin susceptible despite being rifampicin resistant. Our finding thus suggests that the recommended critical testing concentration for rifabutin should be revised.
BibTeX
@article{farhat2019rifampicin,
  author = {Maha Farhat and Jaimie Sixsmith and Róger Calderón and Nathan Hicks and Sarah M. Fortune and Megan Murray},
  title = {{Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates}},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2019},
  doi = {10.1093/jac/dkz048},
}

Loading related content...

Figure